UHSNYSEServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31
UNIVERSAL HEALTH SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$182.29−2.81 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $10.92B
- P/E (TTM)
- 7.4
- Dividend yield
- 0.44%
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
11.5%−0.3 pts over 5 years
Net margin
8.6%+0.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +9.7% | +9.0% | +8.5% | +6.7% | |
| Operating income | +18.6% | +25.7% | +8.0% | +4.7% | |
| Net income | +30.4% | +30.1% | +9.5% | +8.1% | |
| EPS, diluted | +37.3% | +36.2% | +16.0% | +13.1% | |
| Free cash flow | -24.4% | +48.0% | -12.2% | +2.1% | |
| Dividend per share | 0.0% | 0.0% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 16.0% | 16.0% | 21.4% | |
| Return on assets | 7.0% | 7.5% | 9.9% | |
| Current ratio | 1.28 | 1.32 | 1.05 | |
| Debt to equity | 0.91 | 0.61 | 0.65 | |
| Net debt to EBITDA | 2.42× | 1.41× | 1.77× | |
| Interest coverage | 10.2× | 12.8× | 12.8× | |
| Capex to revenue | 5.3% | 6.3% | 5.8% | |
| Diluted shares | 98M | 86M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Universal Health Services generated $7.08B from operations and spent $8.82B on capital expenditure, dividends and share buybacks. 49% of that went back into the business.
Generated
$7.08B
Used
$8.82B
Capital expenditure$4.29B49%Dividends$284.44M3%Share buybacks$4.24B48%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.6%
×Asset turnover1.16×
×Equity multiplier2.15×
=Return on equity, FY202521.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.6% | 1.16× | 2.15× | 21.4% |
| FY2024 | 7.2% | 1.11× | 2.22× | 17.8% |
| FY2023 | 5.0% | 1.04× | 2.28× | 11.9% |
| FY2022 | 5.0% | 1.01× | 2.21× | 11.3% |
| FY2021 | 7.8% | 0.95× | 2.14× | 16.0% |
| FY2020 | 8.2% | 0.92× | 2.13× | 16.0% |
| FY2019 | 7.2% | 0.99× | 2.11× | 15.0% |
| FY2018 | 7.2% | 0.98× | 2.12× | 15.0% |
| FY2017 | 7.2% | 0.99× | 2.21× | 15.8% |
| FY2016 | 7.2% | 0.98× | 2.27× | 16.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$1.49B
- Cash generatingOperating cash flow above zero$1.86B
- Return on assets improvedROA up on the prior year8.2% → 10.3%
- Earnings backed by cashOperating cash flow above net income$1.86B vs $1.49B
- Less leverageLong-term debt to assets fell30.9% → 25.8%
- Better liquidityCurrent ratio rose1.27 → 1.05
- No dilutionShare count did not rise68M → 64M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.13 → 1.20